Overview

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

Status:
Completed
Trial end date:
2012-01-30
Target enrollment:
Participant gender:
Summary
Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin